The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.

“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D. 
 
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
 

Related News Articles

Headline
Clinicians caring for individuals recently evacuated from Afghanistan should alert their state or local health department of suspected measles cases, and…
Headline
Five hospital-led programs today received the 2021 AHA Dick Davidson NOVA Award for their collaborative efforts to improve community health. The winning…
Headline
The AHA has announced the hospital-community partnership teams participating in the 2021 Hospital Community Collaborative. The collaborative is made up of…
Headline
The AHA is accepting applications for its 2022 Dick Davidson NOVA Award through Nov. 19. The award recognizes AHA member hospitals and health systems for their…
Headline
The estimated number of U.S. residents under age 20 with type 1 diabetes increased 45% from 2001 to 2017 to 215 per 100,000, while the number with type 2…
Headline
The Centers for Disease Control and Prevention will use American Rescue Plan Act funds to create a Center for Forecasting and Outbreak Analytics to anticipate…